{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"The number of patients experiencing at least one grade 3+ adverse event using CTCAE version 4.0 is summarized below.","groups":[{"description":"Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.","id":"OG000","title":"Enzalutamide"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"30 days post-treatment, up to 32 months","title":"Number of Patients Experiencing at Least One Grade 3+ Adverse Event Using CTCAE Version 4.0","type":"SECONDARY","unitOfMeasure":"Participants"}